WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results and highlight recent corporate developments.

To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 9257913. A live audio webcast of the event can be accessed via the Investors section of the Company website at

www.eyepointpharma.com

. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert

^®

technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients’ eyes across four U.S. FDA approved products, including YUTIQ

^®

for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina Tartaglia

Stern IR

Direct: (212)-698-8700


[email protected]

Media Contact

Amy Phillips

Green Room Communications

Direct: 412-327-9499


[email protected]